![Digital Journal](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/223/normal/image.png?1371424893)
Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug - Press Release
Digital Journal,
HALIFAX, NOVA SCOTIA--(Marketwired - May 16, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and…